08 nov: Aktier/åbning: ISS og Lundbeck får kursklø efter regnskaber
08 nov: TDC indgår samarbejde med energiselskab
08-11-2017 09:30:23

AroCell AB: Abstract published presenting AroCell TK 210 ELISA from the PROMIX study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017

Relateret indhold

AroCell AB (publ) announces today that the abstract entitled: "Quantification of cell loss in breast cancer during neoadjuvant treatment (NACT) assessed by serum thymidine kinase protein concentrations (sTK1)", by B Tribukait et al was published today by the ESMO Asia congress organizers (

https://cslide.ctimeetingtech.com/asia2017/attendee/confcal/session/calendar?q=Tribukait

).

The investigators quantified cell loss using the AroCell TK 210 ELISA kit to measure serum TK1 in serial samples from 145 breast cancer patients undergoing chemotherapy before surgery. Serum TK1 levels correlated to clinical/radiologically determined tumor response after cycles 2, 4 and 6, as well as pathologically determined response and disease-free survival. (To read the full abstract, please visit the ESMO Asia 2017 website.)

The investigators found that serum TK1 levels measured at the base-line and after completion of four cycles of treatment correlated significantly with clinical/radiological response during treatment and tumor-status at surgery. "This study shows that the reduction of tumor size and response to therapy can be assessed with our TK 210 ELISA" says Jan Stålemark, AroCell CEO. "Our product TK 210 ELISA was used in this study to investigate whether or not TK1 concentration can be a significant predictor of treatment response during chemotherapy of breast cancer. This is another study showing that serum TK1 measured with TK 210 ELISA is a promising biomarker for monitoring treatment response and possibly as a tool in clinical drug development. It gives a prompt signal on whether the new therapy works or not".

For additional information:

Jan Stålemark, CEO

AroCell AB (publ)

Tel: +46(0)706926206

info@arocell.com

www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark,

at 09:30 CET on 08 November 2017.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of the tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see

www.arocell.com

. Redeye AB is AroCell's Certified Adviser.

AroCell press release Final Nov 8 2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: AroCell AB via Globenewswire

Vedhæftet fil: 823952.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Torm/Jyske: Regnskabstal afslører lav pris for aktien

23-01-2018 16:21:15
Jyske Bank har set nærmere på rederiet Torm, og nu sænker banken kursmålet et nøk til 68 kr. fra 72 kr.Banken har dog fortsat et positivt syn på aktien, der fortsat får anbefalingen "køb".Med Torms regnskabsopdatering, der blev præsenteret sammen med planerne om skibskøb og en kapitaludvidelse sent mandag, bliver den lave pris for Torm åbenbar, vurderer Jyske Bank.Den øgede likviditet i aktien, so..

Mærsk/Sydbank: Drilling-salg er realistisk - ikke nødvendigvis elegant

23-01-2018 13:17:37
Det giver fin mening, at A.P. Møller Holding sammen med en ukendt industripartner skulle være tæt på at købe borerigselskabet Maersk Drilling af A.P. Møller-Mærsk.Ifølge Berlingske Business, der har talt med flere anonyme kilder, skulle handlen have en værdi af over 27 mia. kr.- Til trods for stigende oliepriser er drilling stadig et presset marked. Der er ingen af Mærsks konkurrenter, der har pen..

Aktier/åbning: Tryg går til bunds i positivt marked - Mærsk stiger

23-01-2018 09:24:18
Tryg halter tirsdag morgen lidt efter det generelle marked, efter at forsikringskoncernen har skudt regnskabssæsonen ind med tal for fjerde kvartal, der peger i flere retninger.Målt på det forsikringstekniske resultat slog Tryg akkurat analytikerforventningerne. Til gengæld haltede bundlinjen lidt efter forventningerne blandt andet som følge af en lidt skuffende investeringsafkast. Også bruttopræm..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab: Partner melder om vækst i Darzalex-salg på 86 pct.
2
Danske Bank/RBC: Konsensus for udlodninger efter 2018 er for høje
3
Aktier/middag: Salgsrygter sender Mærsk til tops i positivt marked
4
Mærsk/Sydbank: Drilling-salg er realistisk - ikke nødvendigvis elegant
5
Aktier/åbning: Tryg går til bunds i positivt marked - Mærsk stiger

Relaterede aktiekurser

AroCell AB (publ) 5,22 0,8% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. januar 2018 21:00:26
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180122.2 - EUROWEB2 - 2018-01-23 21:00:26 - 2018-01-23 21:00:26 - 1 - Website: OKAY